scispace - formally typeset
F

Felicity D. Chandler

Researcher at Erasmus University Rotterdam

Publications -  15
Citations -  1887

Felicity D. Chandler is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Coronavirus & Serology. The author has an hindex of 7, co-authored 11 publications receiving 1362 citations. Previous affiliations of Felicity D. Chandler include Erasmus University Medical Center.

Papers
More filters
Journal ArticleDOI

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

TL;DR: It is demonstrated that most PCR-confirmed SARS-CoV-2–infected persons seroconverted by 2 weeks after disease onset, and validated and tested various antigens in different in-house and commercial ELISAs, finding that commercial S1 IgG or IgA ELISA were of lower specificity, and sensitivity varied between the 2 assays; the IgAELISA showed higher sensitivity.
Posted ContentDOI

SARS-CoV-2 specific antibody responses in COVID-19 patients

TL;DR: It is demonstrated that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs, and that commercial S1 IgG or IgA ELisAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity.
Journal ArticleDOI

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

TL;DR: The data show that BA.1 and BA.2 have evolved as two distinct antigenic outliers that escape vaccine-induced antibody responses as a result of different antigenic characteristics, which could be used to assess antigenic properties of future SARS-CoV-2 variants of concern that emerge and to decide on the composition of novel spike-based (booster) vaccines.
Journal ArticleDOI

Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence.

TL;DR: Although the DENV NS1 antigen assay was highly specific in this cohort of laboratory confirmed ZIKV-infected travelers, high percentages of cross-reactivity of DENV IgM and IgG ELISÁs of which diagnostic laboratories should be aware are demonstrated.